EP3310396A4 - Hydrogels thérapeutiques à base de nanofibres pour le traitement local des maladies liées au cerveau - Google Patents

Hydrogels thérapeutiques à base de nanofibres pour le traitement local des maladies liées au cerveau Download PDF

Info

Publication number
EP3310396A4
EP3310396A4 EP16812396.6A EP16812396A EP3310396A4 EP 3310396 A4 EP3310396 A4 EP 3310396A4 EP 16812396 A EP16812396 A EP 16812396A EP 3310396 A4 EP3310396 A4 EP 3310396A4
Authority
EP
European Patent Office
Prior art keywords
brain
therapeutic
related diseases
local treatment
nanofiber hydrogels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16812396.6A
Other languages
German (de)
English (en)
Other versions
EP3310396A2 (fr
Inventor
Honggang CUI
Alfredo QUINONES-HINOJOSA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of EP3310396A2 publication Critical patent/EP3310396A2/fr
Publication of EP3310396A4 publication Critical patent/EP3310396A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP16812396.6A 2015-06-16 2016-06-16 Hydrogels thérapeutiques à base de nanofibres pour le traitement local des maladies liées au cerveau Pending EP3310396A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562180264P 2015-06-16 2015-06-16
PCT/US2016/037781 WO2016205459A2 (fr) 2015-06-16 2016-06-16 Hydrogels thérapeutiques à base de nanofibres pour le traitement local des maladies liées au cerveau

Publications (2)

Publication Number Publication Date
EP3310396A2 EP3310396A2 (fr) 2018-04-25
EP3310396A4 true EP3310396A4 (fr) 2019-02-27

Family

ID=57546611

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16812396.6A Pending EP3310396A4 (fr) 2015-06-16 2016-06-16 Hydrogels thérapeutiques à base de nanofibres pour le traitement local des maladies liées au cerveau

Country Status (3)

Country Link
US (1) US11160875B2 (fr)
EP (1) EP3310396A4 (fr)
WO (1) WO2016205459A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017123585A1 (fr) * 2016-01-11 2017-07-20 The Johns Hopkins University Composés amphiphiles de vertéporfine à auto-assemblage (sava) pour le traitement local du cancer
CN112266409B (zh) * 2020-10-28 2022-05-13 南开大学 依托泊苷自组装纳米纤维多肽、制备方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066002A1 (fr) * 2012-10-23 2014-05-01 The Johns Hopkins University Nouveaux médicaments amphiphiles à auto-assemblage et méthodes de synthèse et d'utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524927B2 (en) * 2003-01-29 2009-04-28 The Trustees Of The University Of Pennsylvania Compositions, method and kits relating to deletion mutations of immunodeficiency virus gp120 hypervariable regions
US8378930B2 (en) * 2004-05-28 2013-02-19 Sony Corporation Pixel circuit and display device having symmetric pixel circuits and shared voltage lines
WO2012166705A2 (fr) * 2011-05-31 2012-12-06 Brandeis University Nanofibres et hydrogels supramoléculaires à base de conjugués acide aminé-nucléobase-glucoside
UY35049A (es) * 2012-09-26 2014-04-30 Syngenta Participations Ag ?métodos y composiciones para incrementar la resistencia a nematodos en plantas, plantas, semillas y productos cosechados de las mismas?.
WO2014055810A1 (fr) * 2012-10-04 2014-04-10 Schlumberger Canada Limited Saturation en hydrocarbures à partir des diagraphies de carbone organique total dérivées de spectroscopie nucléaire inélastique et de capture

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066002A1 (fr) * 2012-10-23 2014-05-01 The Johns Hopkins University Nouveaux médicaments amphiphiles à auto-assemblage et méthodes de synthèse et d'utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHOU M ET AL: "Self-assembled peptide-based hydrogels as scaffolds for anchorage-dependent cells", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 30, no. 13, 1 May 2009 (2009-05-01), pages 2523 - 2530, XP025996192, ISSN: 0142-9612, [retrieved on 20090207], DOI: 10.1016/J.BIOMATERIALS.2009.01.010 *

Also Published As

Publication number Publication date
WO2016205459A2 (fr) 2016-12-22
WO2016205459A3 (fr) 2017-01-26
US11160875B2 (en) 2021-11-02
EP3310396A2 (fr) 2018-04-25
US20180360987A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
HRP20190117T1 (hr) iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA
EP3212233A4 (fr) Thérapie combinée pour le traitement d'une maladie
EP3347368A4 (fr) Composés et formulations pour traiter les maladies ophthalmiques
EP3399972A4 (fr) Traitement thérapeutique à faible dose
EP3177732A4 (fr) Compositions et procédés pour le traitement de maladies et états pathologiques ophthalmiques
EP3429605A4 (fr) Agent thérapeutique pour le traitement de maladies, notamment les maladies touchant le système nerveux central
EP3240612A4 (fr) Procédés de traitement de maladies rétiniennes
EP3273955A4 (fr) Traitement de maladies respiratoires
EP3268007A4 (fr) Compositions et procédés thérapeutiques pour le traitement de maladies associées au complément
EP3345002A4 (fr) Sélection de patients pour une polythérapie
EP3097085A4 (fr) Dérivés de benzoxazinone pour le traitement de maladies de la peau
SI3210973T1 (sl) Heteroarilne spojine za zdravljenje oftalmičnih bolezni
EP3192875A4 (fr) Composition pharmaceutique à libération prolongée destinée au traitement et à la prévention de maladies ophtalmiques
EP3192524A4 (fr) Préparation à base de hgf utilisable pour le traitement de maladies du système nerveux
EP3413898A4 (fr) Utilisation de tréhalose pour le traitement de maladies neurologiques
EP3340974A4 (fr) Méthodes de traitement de maladies
EP3096775A4 (fr) Socs mimétiques pour le traitement de maladies
EP3283457A4 (fr) Composés et procédés pour le traitement de maladies neurodégénératives
EP3119387A4 (fr) Compositions pour le traitement de maladies et de troubles dermatologiques
EP3154637A4 (fr) Traitement de maladies virales de la peau
EP3310396A4 (fr) Hydrogels thérapeutiques à base de nanofibres pour le traitement local des maladies liées au cerveau
EP3402511A4 (fr) Compositions et procédés de traitement de maladies oculaires
EP3182980A4 (fr) Traitement de maladies liées à une déficience de la glycosylation
IL259381B (en) Miravegron for the treatment of retinal diseases
EP3560505A4 (fr) Nouvel agent thérapeutique pour maladies de type prionoïdes

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180103

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: QUINONES-HINOJOSA, ALFREDO

Inventor name: CUI, HONGGANG

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0049000000

Ipc: A61K0047640000

A4 Supplementary search report drawn up and despatched

Effective date: 20190124

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20190118BHEP

Ipc: A61K 49/00 20060101ALI20190118BHEP

Ipc: A61K 47/69 20170101ALI20190118BHEP

Ipc: A61K 47/64 20170101AFI20190118BHEP

Ipc: B82Y 5/00 20110101ALI20190118BHEP

Ipc: A61K 49/10 20060101ALI20190118BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20201002

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230515